Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 5:8:655100.
doi: 10.3389/fmed.2021.655100. eCollection 2021.

What's New in the Treatment of Systemic Lupus Erythematosus

Stamatis Nick Liossis  1   2 , Chrysanthi Staveri  1
Affiliations
Review

What's New in the Treatment of Systemic Lupus Erythematosus

Stamatis Nick Liossis et al. Front Med (Lausanne). .

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune multisystem disease with a variable presentation and manifestations ranging from mild to severe or even life-threatening. There is an ongoing and unmet need for novel, disease-specific, effective and safe treatment modalities. The aim of this review is to summarize data on SLE treatment that have emerged over the last 3 years. We will put emphasis on studies evaluating potential treatments on severe lupus manifestations such as lupus nephritis. Despite the existence of several therapeutic agents in SLE, the disease keeps causing significant morbidity. It is encouraging that a variety of therapeutic options are currently under investigation, although there are occasional trial failures.

Keywords: B cell; clinical trial; lupus nephritis; systemic lupus erythematosus; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Molecules targeted therapeutically in patients with SLE.
See this image and copyright information in PMC

References

    1. Maidhof W, Hilas O. Lupus: an overview of the disease and management options. PT. (2012) 37:240–9. - PMC - PubMed
    1. Liossis SN, Kovacs B, Dennis G, Kammer GM, Tsokos GC. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest. (1996) 98:2549–57. 10.1172/JCI119073 - DOI - PMC - PubMed
    1. Staveri C, Liossis SN. Rituximab for SLE refractory to conventional treatment: results of a cohort evaluating efficacy and long-term outcome. Clin Exp Rheumatol. (2016) 34:S5.
    1. Liossis SC, Staveri C. B cell-based treatments in SLE: past experience and current directions. Curr Rheumatol Rep. (2017) 19:78. 10.1007/s11926-017-0707-z - DOI - PubMed
    1. Peng SL, Madaio MP, Hughes DP, Crispe IN, Owen MJ, Wen L, et al. . Murine lupus in the absence of alpha beta T cells. J Immunol. (1996) 156:4041–9. - PubMed